Description

Pramipex (pramipexole) tablets 0.25 mg. №30

Ingredients

Active ingredient: Pramipexole dihydrochloride monohydrate.
Other ingredients: Lactose monohydrate, maize starch, povidone K25, magnesium stearate.

Dosage

Recommended dosage: The usual starting dose is 0.125 mg taken three times a day. Dosage may be increased gradually every 5-7 days. Consult a healthcare professional for personalized dosing.

Indications

Pramipex is indicated for the treatment of Parkinson’s disease and Restless Legs Syndrome (RLS).

Contraindications

Do not use Pramipex if:

• You are allergic to pramipexole or any other ingredients in the tablets.
• You have severe kidney problems.
• You are taking other medications that interact with pramipexole.

Directions

How to take: Swallow the tablets whole with a glass of water. It can be taken with or without food. Follow the dosage instructions provided by your doctor.

Scientific Evidence

Pramipexole, the active ingredient in Pramipex tablets, is a dopamine agonist that works by stimulating dopamine receptors in the brain. Studies have shown that pramipexole effectively improves motor symptoms in patients with Parkinson’s disease and reduces symptoms of Restless Legs Syndrome.

Additional Information

Pramipex tablets have been well-tolerated in clinical trials, with common side effects including nausea, dizziness, and drowsiness. It is important to follow the prescribed dosage and report any unusual symptoms to your healthcare provider.

Pharmacological Effects

Pramipexole acts as a selective dopamine agonist, primarily stimulating dopamine D2/D3 receptors. By mimicking the action of dopamine, pramipexole helps to improve motor function in Parkinson’s disease and alleviate symptoms of Restless Legs Syndrome.

Clinical Trials and Comparative Effectiveness

Clinical trials have demonstrated the efficacy of pramipexole in improving motor symptoms and quality of life in patients with Parkinson’s disease. Compared to other dopamine agonists, pramipexole has shown similar effectiveness with a favorable side effect profile.

References:
1. Mizuno Y, et al. Pramipexole for the treatment of early Parkinson’s disease. Neuropsychiatric Disease and Treatment. 2006;2(4):411-421.
2. Trenkwalder C, et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Movement Disorders. 2008;23(13):207-213.